pharmatechoutlook

Cannabics Pharmaceuticals Unveils WanaCapsxr Capsules forCannabis Patients

By Pharma Tech Outlook | Friday, November 30, 2018

BETHESDA, MD:Cannabics Pharmaceuticals, a public company with research and development of advanced and sophisticated cannabinoid-based treatments and therapies has announced that its partner Wana Products has unveiled "WanaCapsxr," a series of extended release cannabis capsules.

The three formulations in which the capsules will be offered to the patients include capsules with a 10:1 CBD to THC ratio (WanaCapsxr High CBD Capsules), a 10:1 THC to CBD ratio (WanaCapsxr High THC Capsules), and a balanced formulation with 1:1 THC:CBD ratio (WanaCapsxr THC/CBD Balanced Capsules).

According to Nancy Whiteman, co-ownerof Wana Products, the capsules are given to the patients once or twice daily so as to address the concerns of cannabis patients which is that the initial high peak of cannabinoid activity soon after administration which can cause uncomfortable side effects such as disorientation and dizziness. Instead, these capsules offer patients with long-lasting, stable effect without the ups and downs.

"Cannabics researchers are making breakthroughs in the medical evolution of cannabis, and WanaCapsxr is on the leading edge of those advancements," says Dr. EyalBallan, Chief Scientist, Cannabics Pharmaceuticals. "Wana's new XR product will help legal medical marijuana states approach the roll out of medical cannabis in a new, controlled, stable and effective way."

New Editions